InsidersTradesSigma
Total declarations
Companies
▲ Purchases (12 ops.)
▼ Sales (4 ops.)
Insider track record
ExecutiveDisclosed buys
12
Disclosed sells
4
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the complete record of transactions filed by Graham G. Walmsley, Director. Director active across 2 companies, notably Akero Therapeutics, Inc.. In total, 20 filings have been logged. Split: 12 buys · 4 sells. Total volume traded: €76.1m. History available since 19 May 2023. The latest transaction was disclosed on 25 March 2025 (Acquisition). Regulator: SEC (Form 4). The full history is openly available.
Declarations20 total
93,000 sharesCommon StockSEC:0001193125-25-312122
93,000 sharesCommon StockSEC:0001193125-25-312122:0
1,200,000 sharesCommon StockSEC:0001193125-25-312122:1
9,398 sharesCommon StockSEC:0001193125-25-312122:2
91,309 shares@ US$44.7478.7% of flowCommon StockSEC:0000950170-25-046271:0
Ideal exit: 20 Dec 2025 (T+270)
200,000 shares@ US$48.0021.2% of flowCommon StockSEC:0000950170-25-016559:0
Ideal exit: 27 Oct 2025 (T+270)
700,761 shares@ US$6.7513.8% of flowCommon StockSEC:0000935836-24-000764:0
700,761 shares@ US$6.7513.7% of flowCommon StockSEC:0000935836-24-000763:0
700,000 shares@ US$14.8529.2% of flowCommon StockSEC:0000935836-24-000744:0
700,000 shares@ US$14.8529.2% of flowCommon StockSEC:0000935836-24-000425:0
508,130 shares@ US$9.8414.2% of flowCommon StockSEC:0000935836-23-000733:0
Ideal exit: 8 Jun 2024 (T+270)
50,000 shares@ US$19.80482.1% of flowCommon StockSEC:0000950170-23-069509:0
Ideal exit: 3 Sept 2024 (T+270)
50,000 shares@ US$16.89671.8% of flowCommon StockSEC:0000950170-23-067951:0
Ideal exit: 26 Aug 2024 (T+270)
50,000 shares@ US$16.99461.8% of flowCommon StockSEC:0000950170-23-067951:1
Ideal exit: 27 Aug 2024 (T+270)
25,000 shares@ US$42.0592.2% of flowCommon StockSEC:0000950170-23-041440:0
Ideal exit: 4 May 2024 (T+270)
30,000 shares@ US$42.69032.7% of flowCommon StockSEC:0000950170-23-036694:0
Ideal exit: 23 Apr 2024 (T+270)
25,000 shares@ US$43.2612.3% of flowCommon StockSEC:0000950170-23-036694:1
Ideal exit: 27 Apr 2024 (T+270)
400,000 shares@ US$26.0023.9% of flowCommon StockSEC:0000899243-23-015665:0
Ideal exit: 16 Jun 2023 (T+270)
400,000 shares@ US$26.0022.5% of flowCommon StockSEC:0000950170-23-023738:0
Ideal exit: 15 Jun 2024 (T+270)
120,000 shares@ US$42.0010.8% of flowCommon StockSEC:0000950170-23-023738:1
Ideal exit: 13 Feb 2024 (T+270)
20 of 20 declarations
About Graham G. Walmsley
Graham G. Walmsley is a Director at Akero Therapeutics, Inc. He contributes to the governance of the company and strategic decision-making. Graham brings his expertise in biotechnology to help Akero innovate and grow in the market.
